299 related articles for article (PubMed ID: 17469119)
1. Surgery in malignant pancreatic neuroendocrine tumors.
Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
3. Resection of pancreatic neuroendocrine tumors: results of 70 cases.
Kazanjian KK; Reber HA; Hines OJ
Arch Surg; 2006 Aug; 141(8):765-9; discussion 769-70. PubMed ID: 16924083
[TBL] [Abstract][Full Text] [Related]
4. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
5. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
Teh SH; Deveney C; Sheppard BC
Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
[TBL] [Abstract][Full Text] [Related]
6. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M
Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361
[TBL] [Abstract][Full Text] [Related]
7. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
8. Extended surgery for advanced pancreatic endocrine tumours.
Kleine M; Schrem H; Vondran FW; Krech T; Klempnauer J; Bektas H
Br J Surg; 2012 Jan; 99(1):88-94. PubMed ID: 22135173
[TBL] [Abstract][Full Text] [Related]
9. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.
Matthews BD; Heniford BT; Reardon PR; Brunicardi FC; Greene FL
Am Surg; 2000 Dec; 66(12):1116-22; discussion 1122-3. PubMed ID: 11149582
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
[TBL] [Abstract][Full Text] [Related]
12. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
13. Combined resection of the liver and pancreas for malignancy.
Hemming AW; Magliocca JF; Fujita S; Kayler LK; Hochwald S; Zendejas I; Kim RD
J Am Coll Surg; 2010 May; 210(5):808-14, 814-6. PubMed ID: 20421055
[TBL] [Abstract][Full Text] [Related]
14. [Liver resection for non-colorectal, non-neuroendocrine liver metastases--is hepatic resection justified as part of the oncosurgical treatment?].
Lehner F; Ramackers W; Bektas H; Becker T; Klempnauer J
Zentralbl Chir; 2009 Sep; 134(5):430-6. PubMed ID: 19757343
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
Sarmiento JM; Heywood G; Rubin J; Ilstrup DM; Nagorney DM; Que FG
J Am Coll Surg; 2003 Jul; 197(1):29-37. PubMed ID: 12831921
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery in advanced endocrine tumours of the pancreas.
Pederzoli P; Falconi M; Bonora A; Salvia R; Sartori N; Contro C; Marcucci S; Bassi C
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S207-12. PubMed ID: 10604132
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
Hishinuma S; Ogata Y; Tomikawa M; Ozawa I; Inoue K; Katano S; Tsukiyama I
J Hepatobiliary Pancreat Surg; 2005; 12(3):235-42. PubMed ID: 15995813
[TBL] [Abstract][Full Text] [Related]
18. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
19. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases.
Grazi GL; Cescon M; Pierangeli F; Ercolani G; Gardini A; Cavallari A; Mazziotti A
Hepatogastroenterology; 2000; 47(32):481-6. PubMed ID: 10791218
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
